nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.03.2013 | Original article

In vitro hypoxic cytotoxicity and hypoxic radiosensitization

Efficacy of the novel 2-nitroimidazole N,N,N-tris[2-(2-nitro-1H-imidazol-1-yl)ethyl]amine

verfasst von: M. Langenbacher, Dr. R.J. Abdel-Jalil, W. Voelter, M. Weinmann, S.M. Huber

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Tumor hypoxia is a major problem in radiation therapy of solid tumors because of the radiosensitizing effect of oxygen. Nitroimidazole-containing compounds are oxygen mimetics accumulating in hypoxic tumor areas. However, the broad use of 2-nitroimidazoles as a hypoxic radiosensitizer is limited by their partially low efficacy and/or high neurotoxicity.

Materials and methods

Here, we characterized the in vitro hypoxic cytotoxicity and hypoxic radiosensitizing efficacy of N,N,N-tris [2-(2-nitro-1H-imidazol-1-yl)ethyl]amine (PRC) in a hypoxia-sensitive lymphoma and a hypoxia-resistant glioblastoma cell line by colony formation assay and flow cytometry.

Results

PRC exerted high hypoxic cytotoxic and radiosensitizing action on both cell lines at almost absent toxicity under normoxic conditions. In particular, under hypoxia, but not normoxia, PRC targeted the mitochondria resulting in oxidative stress, G₂/M cell cycle arrest, and triggering of the intrinsic apoptosis pathway.

Conclusion

Our in vitro findings suggest that PRC might be a promising new 2-nitroimidazole for improving radiation therapy of hypoxic tumors in vivo.

Bayer C, Vaupel P (2012) Acute versus chronic hypoxia in tumors: Controversial data concerning time frames and biological consequences. Strahlenther Onkol 188:616–627PubMedCrossRef

Maftei CA, Bayer C, Shi K et al (2011) Quantitative assessment of hypoxia subtypes in microcirculatory supply units of malignant tumors using (immuno-)fluorescence techniques. Strahlenther Onkol 187:260–266PubMedCrossRef

Maftei CA, Bayer C, Shi K, Vaupel P (2012) Intra- and intertumor heterogeneities in total, chronic, and acute hypoxia in xenografted squamous cell carcinomas: detection and quantification using (immuno-) fluorescence techniques. Strahlenther Onkol 188:606–615PubMedCrossRef

Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26:225–239PubMedCrossRef

Johansen I, Brustad T, Rupp WD (1975) DNA strand breaks measured within 100 ms of irradiation of Escherichia coli by 4 MeV electrons. Proc Natl Acad Sci U S A 72:167–171PubMedCrossRef

Schilling D, Bayer C, Emmerich K et al (2012) Basal HIF-1alpha expression levels are not predictive for radiosensitivity of human cancer cell lines. Strahlenther Onkol 188:353–358PubMedCrossRef

Staab A, Fleischer M, Loeffler J et al (2011) Small interfering RNA targeting HIF-1alpha reduces hypoxia-dependent transcription and radiosensitizes hypoxic HT 1080 human fibrosarcoma cells in vitro. Strahlenther Onkol 187:252–259PubMedCrossRef

Brown JM (1999) The hypoxic cell: a target for selective cancer therapy–eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59:5863–5870PubMed

Bischoff P, Altmeyer A, Dumont F (2009) Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers. Expert Opin Ther Pat 19:643–662PubMedCrossRef

10.

Overgaard J (2011) Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck—a systematic review and meta-analysis. Radiother Oncol 100:22–32PubMedCrossRef

11.

Hay MP, Sykes BM, Denny WA, Wilson WR (1999) A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl) carbony l]-1,2-dihydro-3H–benz [E] indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT. Bioorg Med Chem Lett 9:2237–2242PubMedCrossRef

12.

Shimamura M, Nagasawa H, Ashino H et al (2003) A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors. Br J Cancer 88:307–313PubMedCrossRef

13.

Tilby MJ, Loverock PS (1983) Measurements of DNA double-strand break yields in E. coli after rapid irradiation and cell inactivation: the effects of inactivation technique and anoxic radiosensitizers. Radiat Res 96:309–321PubMedCrossRef

14.

Shibamoto Y, Ono K, Takahashi M et al (1986) An in vitro and in vivo screening system for new hypoxic cell radiosensitizers using EMT6 cells. Jpn J Cancer Res 77:1027–1033PubMed

15.

Murayama C, Tanaka N, Miyamoto Y et al (1987) In vitro and in vivo radiosensitizing effects of 2-nitroimidazole derivatives with sugar component. Strahlenther Onkol 163:385–390PubMed

16.

Skov KA, MacPhail S (1994) Low concentrations of nitroimidazoles: effective radiosensitizers at low doses. Int J Radiat Oncol Biol Phys 29:87–93PubMedCrossRef

17.

Shibamoto Y, Kubota T, Kishii K, Tsujitani M (2000) Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole. Radiother Oncol 56:265–270PubMedCrossRef

18.

Sugie C, Shibamoto Y, Ito M et al (2005) Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo. J Radiat Res 46:453–459PubMedCrossRef

19.

Abe C, Uto Y, Nakae T et al (2011) Evaluation of the in vivo radiosensitizing activity of etanidazole using tumor-bearing chick embryo. J Radiat Res (Tokyo) 52:208–214CrossRef

20.

Lee DJ, Pajak TF, Stetz J et al (1989) A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79–04). Int J Radiat Oncol Biol Phys 16:465–470PubMedCrossRef

21.

Overgaard J, Bentzen SM, Kolstad P et al (1989) Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 16:1069–1072PubMedCrossRef

22.

Overgaard J, Hansen HS, Andersen AP et al (1989) Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 16:1065–1068PubMedCrossRef

23.

Wasserman TH, Lee DJ, Cosmatos D et al (1991) Clinical trials with etanidazole (SR-2508) by the Radiation Therapy Oncology Group (RTOG). Radiother Oncol 20(Suppl 1):129–35PubMedCrossRef

24.

Lee DJ, Cosmatos D, Marcial VA et al (1995) Results of an RTOG phase III trial (RTOG 85–27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 32:567–576PubMedCrossRef

25.

Grigsby PW, Winter K, Wasserman TH et al (1999) Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: final results of RTOG 80–05. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 44:513–517PubMedCrossRef

26.

Dayes IS, Abuzallouf S (2005) Local tumour control in women with carcinoma of the cervix treated with the addition of nitroimidazole agents to radiotherapy: a meta-analysis. Br J Radiol 78:777–782PubMedCrossRef

27.

Overgaard J, Hansen HS, Overgaard M et al (1998) A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5–85. Radiother Oncol 46:135–146PubMedCrossRef

28.

Overgaard J, Eriksen JG, Nordsmark M et al (2005) Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6:757–764PubMedCrossRef

29.

Toustrup K, Sorensen BS, Lassen P et al (2012) Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 102:122–129PubMedCrossRef

30.

Abdel-Jalil RJ, Voelter W, Loeffler D et al (2008) Crystal structure of N,N,N-tris [2-(2-nitro-1 H-imidazol-1-yl) ethyl] amine, C15H18N10O6. Z Kristallogr (NCS) 223:505–506

31.

Jiang J, Tang YL, Liang XH (2011) EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol Ther 11:714–723PubMedCrossRef

32.

Chang Q, Jurisica I, Do T, Hedley DW (2011) Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res 71:3110–3120PubMedCrossRef

33.

Rohwer N, Cramer T (2011) Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 14:191–201PubMedCrossRef

34.

Cullis PM, Jones GD, Symons MC, Lea JS (1987) Electron transfer from protein to DNA in irradiated chromatin. Nature 330:773–774PubMedCrossRef

35.

Balasubramanian B, Pogozelski WK, Tullius TD (1998) DNA strand breaking by the hydroxyl radical is governed by the accessible surface areas of the hydrogen atoms of the DNA backbone. Proc Natl Acad Sci U S A 95):9738–9743PubMedCrossRef

36.

Cullis PM, Jones GDD, Lea J et al (1987) The effects of ionizing radiation on deoxyribonucleic acid. Part 5. The role of thiols in chemical repair. J Chem Soc, Perkin Trans 2:1907–1914

37.

Revesz L (1985) The role of endogenous thiols in intrinsic radioprotection. Int J Radiat Biol Relat Stud Phys Chem Med 47:361–368PubMed

38.

Schans GP van der, Vos O, Roos-Verheij WS, Lohman PH (1986) The influence of oxygen on the induction of radiation damage in DNA in mammalian cells after sensitization by intracellular glutathione depletion. Int J Radiat Biol Relat Stud Phys Chem Med 50:453–470PubMedCrossRef

39.

Vos O, Schans GP van der, Roos-Verheij WS (1986) Reduction of intracellular glutathione content and radiosensitivity. Int J Radiat Biol Relat Stud Phys Chem Med 50:155–165PubMedCrossRef

40.

Frankenberg D, Kistler M, Eckardt-Schupp F (1987) Effect of cellular glutathione content on the induction of DNA double strand breaks by 25 MeV electrons. Int J Radiat Biol Relat Stud Phys Chem Med 52:185–190PubMedCrossRef

41.

Frankenberg D, Michael BD, Frankenberg-Schwager M, Harbich R (1990) Fast kinetics of the oxygen effect for DNA double-strand breakage and cell killing in irradiated yeast. Int J Radiat Biol 57:485–501PubMedCrossRef

42.

Bump EA, Brown JM (1990) Role of glutathione in the radiation response of mammalian cells in vitro and in vivo. Pharmacol Ther 47:117–136PubMedCrossRef

43.

Prise KM, Folkard M, Davies S, Michael BD (1990) The irradiation of V79 mammalian cells by protons with energies below 2 MeV. Part II. Measurement of oxygen enhancement ratios and DNA damage. Int J Radiat Biol 58:261–277PubMedCrossRef

44.

Rosander K, Zackrisson B (1995) DNA damage in human endothelial cells after irradiation in anoxia. Acta Oncol 34:111–116PubMedCrossRef

45.

Nunn A, Linder K, Strauss HW (1995) Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 22:265–280PubMedCrossRef

46.

Moselen JW, Hay MP, Denny WA, Wilson WR (1995) N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl) butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug. Cancer Res 55:574–580PubMed

47.

Lee HH, Palmer BD, Wilson WR, Denny WA (1998) Synthesis and hypoxia-selective cytotoxicity of a 2-nitroimidazole mustard. Bioorg Med Chem Lett 8:1741–1744PubMedCrossRef

48.

Papadopoulou MV, Rosenzweig HS, Bloomer WD (2004) Synthesis of a novel nitroimidazole-spermidine derivative as a tumor-targeted hypoxia-selective cytotoxin. Bioorg Med Chem Lett 14:1519–1522PubMedCrossRef

49.

Papadopoulou MV, Rosenzweig HS, Bloomer WD (2004) Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers. Bioorg Med Chem Lett 14:1523–1525PubMedCrossRef

50.

Brezden CB, McClelland RA, Rauth AM (1994) Mechanism of the selective hypoxic cytotoxicity of 1-methyl-2-nitroimidazole. Biochem Pharmacol 48:361–370PubMedCrossRef

51.

Biesalski HK, Lambert C, Frank J (2004) Antioxidant micronutrients as additives in oncology. Onkologe 10:230–243CrossRef

Titel: In vitro hypoxic cytotoxicity and hypoxic radiosensitization
Efficacy of the novel 2-nitroimidazole N,N,N-tris[2-(2-nitro-1H-imidazol-1-yl)ethyl]amine
verfasst von: M. Langenbacher
Dr. R.J. Abdel-Jalil
W. Voelter
M. Weinmann
S.M. Huber
Publikationsdatum: 01.03.2013
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 3/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0273-2

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

In vitro hypoxic cytotoxicity and hypoxic radiosensitization

Efficacy of the novel 2-nitroimidazole N,N,N-tris[2-(2-nitro-1H-imidazol-1-yl)ethyl]amine

Abstract

Background and purpose

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background and purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Cyclin D1, EGFR, and Akt/mTOR pathway

Erratum to: Should hyperthermia be included in the benefit catalogue for oncologic indications? Commercial interests are presumed behind the editorial of R. Sauer et al.

Mitteilungen der Fachgesellschaften

Dysphagia after definitive radiotherapy for head and neck cancer

Zum Gedenken an Roch Kowalski

Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie